Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy

BACKGROUND: Anti-programmed cell death protein 1 (PD-1) antibodies are now routinely administered for metastatic melanoma and for increasing numbers of other cancers, but still only a fraction of patients respond. Better understanding of the modes of action and predictive biomarkers for clinical out...

Descripción completa

Detalles Bibliográficos
Autores principales: Bochem, Jonas, Zelba, Henning, Spreuer, Janine, Amaral, Teresa, Wagner, Nikolaus B, Gaissler, Andrea, Pop, Oltin T, Thiel, Karolin, Yurttas, Can, Soffel, Daniel, Forchhammer, Stephan, Sinnberg, Tobias, Niessner, Heike, Meier, Friedegund, Terheyden, Patrick, Königsrainer, Alfred, Garbe, Claus, Flatz, Lukas, Pawelec, Graham, Eigentler, Thomas K, Löffler, Markus W, Weide, Benjamin, Wistuba-Hamprecht, Kilian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8693089/
https://www.ncbi.nlm.nih.gov/pubmed/34933966
http://dx.doi.org/10.1136/jitc-2021-003439

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8693089/
https://www.ncbi.nlm.nih.gov/pubmed/34933966
http://dx.doi.org/10.1136/jitc-2021-003439

Ejemplares similares